How many Ivonescimab clinical trials are there?

87 Ivonescimab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 50 are actively recruiting participants.

Are Ivonescimab clinical trials recruiting in 2026?

Yes — 50 Ivonescimab trials are actively recruiting in 2026, with 312 U.S. sites across 40 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Ivonescimab being studied for?

Ivonescimab is being studied for Non-Small Cell Lung Cancer, NSCLC, Neoadjuvant Therapy, Pancreatic Cancer, Breast Cancer and 129 more. The trials are grouped by indication on this page.

What phase is Ivonescimab in?

Ivonescimab clinical trials span 7 Phase 3, 64 Phase 2, 3 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Ivonescimab clinical trials?

The lead sponsor across the most Ivonescimab trials is M.D. Anderson Cancer Center, with 51 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Ivonescimab Clinical Trials (2026): 87 Studies for Non-Small Cell Lung Cancer & NSCLC

Creator: Hipa.ai Research
Published: 2026-05-14T21:48:18.097Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 18, 2026.

87 Ivonescimab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 66 indications (including Non-Small Cell Lung Cancer & NSCLC) and 17,325 total planned enrollment. 7 Phase 3 Ivonescimab trials and 64 Phase 2 are listed. 85 Ivonescimab clinical trials are actively recruiting at 312 U.S. sites across 40 states. Most recent activity: NCT07359456 (Aug 2033).

Where to Participate: All Ivonescimab Trial Sites in the U.S. (312 sites across 40 states)

Every actively recruiting Ivonescimabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	University of Alabama at Birmingham	Birmingham35294	NCT01042379	Map
AZ	Clinical Study Site	Chandler85224	NCT06767514	Map
AZ	Clinical Study Site	Goodyear85338	NCT07228832	Map
AZ	Banner University Medical Center	Phoenix85006	NCT05899608	Map
AZ	Clinical Study Site	Phoenix85006	NCT06767514	Map
AZ	TMC Healthcare	Tucson85711	NCT05899608	Map
AR	Clinical Study Site	Hot Springs71913	NCT06767514	Map
AR	Genesis Cancer and Blood Institute	Hot Springs71913	NCT05899608	Map
AR	University of Arkansas	Little Rock72205	NCT05899608	Map
CA	LA Cancer Network	Anaheim92801	NCT05899608	Map
CA	Clinical Study Site	Beverly Hills90211	NCT07228832	Map
CA	Clinical Study Site	Beverly Hills90212	NCT07228832	Map
CA	Clinical Study Site	Cerritos90703	NCT06767514	Map
CA	Clinical Study Site	Cerritos90703	NCT07228832	Map
CA	The Oncology Institute of Hope & Innovation	Cerritos90703	NCT05899608	Map
CA	Clinical Study Site	Corona92882	NCT07228832	Map
CA	University of California - Davis, Comprehensive Cancer Center	Davis95817	NCT01042379	Map
CA	City of Hope	Duarte91010	NCT01042379	Map
CA	City of Hope Medical Center	Duarte91010	NCT07226544	Map
CA	Clinical Study Site	Duarte91010	NCT07228832	Map
CA	Clinical Study Site	Fountain Valley92708	NCT07228832	Map
CA	Clinical Study Site	Glendale91204	NCT06767514	Map
CA	Clinical Study Site	Huntington Beach92648	NCT07228832	Map
CA	Clinical Study Site	Irvine92612	NCT06767514	Map
CA	Clinical Study Site	Irvine92612	NCT07228832	Map
CA	Clinical Study Site	Irvine92618	NCT07228832	Map
CA	University of California San Diego	La Jolla92093-0698	NCT01042379	Map
CA	Cedar Sinai Medical Center	Los Angeles90048	NCT05899608	Map
CA	Cedars-Sinai Medical Center	Los Angeles90048	NCT07017673	Map
CA	Cedars-Sinai Medical Center Beverly Hills	Los Angeles90211	NCT07017673	Map
CA	Clinical Study Site	Los Angeles90067	NCT06767514	Map
CA	Clinical Study Site	Los Angeles90027	NCT07228832	Map
CA	Clinical Study Site	Los Angeles90067	NCT07228832	Map
CA	Clinical Study Site	Los Angeles90404	NCT07228832	Map
CA	UCLA / Jonsson Comprehensive Cancer Center	Los Angeles90095	NCT06980077	Map
CA	University of Southern California	Los Angeles90033	NCT01042379	Map
CA	University of Southern California (USC)	Los Angeles90033	NCT05899608	Map
CA	Valkyrie Clinical Trials	Los Angeles90067	NCT05899608	Map
CA	Clinical Study Site	Mountain View94040	NCT06767514	Map
CA	Clinical Study Site	Murrieta92562	NCT06767514	Map
CA	Clinical Study Site	Murrieta92562	NCT07228832	Map
CA	Clinical Study Site	Newport Beach92663	NCT06767514	Map
CA	HOAG Memorial Hospital Presbyterian	Newport Beach92663	NCT01042379	Map
CA	Clinical Study Site	Orange92868	NCT07228832	Map
CA	Clinical Study Site	Pasadena91030	NCT07228832	Map
CA	Clinical Study Site	Roseville95661	NCT06767514	Map
CA	Clinical Study Site	Sacramento95816	NCT06767514	Map
CA	Sutter Institute for Medical Research	Sacramento95816	NCT05899608	Map
CA	UC Davis Medical Center	Sacramento95817	NCT05899608	Map
CA	Clinical Study Site	San Diego92123	NCT06767514	Map
CA	Clinical Study Site	San Francisco94115	NCT06767514	Map
CA	University of California at San Francisco (UCSF)	San Francisco94115	NCT06980077	Map
CA	University of California San Francisco (UCSF)	San Francisco94115	NCT01042379	Map
CA	Clinical Study Site	Santa Ana92705	NCT06767514	Map
CA	UCLA	Santa Monica90404	NCT07070466	Map
CA	University of California Los Angeles (UCLA)	Santa Monica90404	NCT05899608	Map
CA	Providence Medical Foundation	Santa Rosa95403	NCT05899608	Map
CA	Clinical Study Site	Torrance90503	NCT07228832	Map
CA	Hunt Cancer Institute, an Affiliate of CS Cancer	Torrance90505	NCT07017673	Map
CA	Clinical Study Site	Upland91786	NCT07228832	Map
CA	Kaiser Permanente	Vallejo94589	NCT05899608	Map
CA	Clinical Study Site	West Hollywood90048	NCT07228832	Map
CA	Clinical Study Site	Whittier90602	NCT06767514	Map
CO	Clinical Study Site	Aurora80045	NCT06767514	Map
CO	University of Colorado Cancer Center	Aurora80045	NCT01042379	Map
CO	Clinical Study Site	Grand Junction81505	NCT06767514	Map
CO	Clinical Study Site	Greeley80631	NCT06767514	Map
CO	Clinical Study Site	Lone Tree80124	NCT06767514	Map
CO	Rocky Mountain Cancer	Lone Tree80124	NCT05899608	Map
CO	Banner MD Anderson Cancer Center at North Colorado Medical Center	Loveland80538	NCT05899608	Map
CO	Clinical Study Site	Loveland80538	NCT06767514	Map
CT	Clinical Study Site	Hartford06106	NCT07228832	Map
CT	Hartford Hospital	Hartford06053	NCT05899608	Map
CT	Clinical Study Site	New Haven06520-8028	NCT07228832	Map
CT	Yale Cancer Center	New Haven06510	NCT01042379	Map
CT	Yale University	New Haven06510	NCT05899608	Map
CT	Clinical Study Site	Norwich06360	NCT07228832	Map
CT	Eastern Connecticut Hematology and Oncology Associates	Norwich06360	NCT07397338	Map
DC	Georgetown University Medical Center	Washington D.C.20007	NCT01042379	Map
FL	Clinical Study Site	Fort Lauderdale33317	NCT06767514	Map
FL	Florida Cancer Specialists & Research Institute (FCS)-East	Fort Myers33901	NCT05899608	Map
FL	BioResearch Partner- Hialeah Hospital	Hialeah33013	NCT05899608	Map
FL	Clinical Study Site	Hialeah33013	NCT06767514	Map
FL	Clinical Study Site	Hialeah33013	NCT07228832	Map
FL	Cancer Specialists of North Florida	Jacksonville32256	NCT05899608	Map
FL	Clinical Study Site	Jacksonville32256	NCT06767514	Map
FL	Mayo Clinic	Jacksonville32224	NCT05899608	Map
FL	Clinical Study Site	Miami33155	NCT06767514	Map
FL	Clinical Study Site	Miami33176	NCT07228832	Map
FL	University of Miami	Miami33136	NCT07057791	Map
FL	Clinical Study Site	North Venice34275	NCT06767514	—
FL	Ocala Oncology	Ocala34474	NCT05899608	Map
FL	Clinical Study Site	Orlando32822	NCT06767514	Map
FL	Clinical Study Site	Orlando32806	NCT07228832	Map
FL	Cancer Care of Brevard	Palm Bay32901	NCT05899608	Map
FL	Memorial Cancer Institute	Pembroke Pines33028	NCT05899608	Map
FL	Ascension Sacred Heart Health System	Pensacola32504	NCT05899608	Map
FL	Clinical Study Site	Pensacola32504	NCT06767514	Map
FL	BRCR Medical Center Inc	Plantation33322	NCT05899608	Map
FL	Clinical Study Site	Plantation33322	NCT06767514	Map
FL	Clinical Study Site	Plantation33323	NCT06767514	Map
FL	Clinical Study Site	Plantation33322	NCT07228832	Map
FL	Clinical Study Site	Port Saint Lucie34952	NCT07228832	Map
FL	Exigent Network	St. Petersburg33709	NCT05899608	Map
FL	Florida Cancer Specialists & Research Institute (FCS) - North	St. Petersburg33705	NCT05899608	Map
FL	Clinical Study Site	Tallahassee32308	NCT06767514	Map
FL	BRCR Medical Center Inc.	Tamarac33321	NCT05899608	Map
FL	Clinical Study Site	Tamarac33321	NCT06767514	Map
FL	Clinical Study Site	Tamarac33321	NCT07228832	Map
FL	H. Lee Moffitt Cancer Center and Research Institute	Tampa33612	NCT01042379	Map
FL	Moffitt Cancer Center	Tampa33612	NCT01042379	Map
FL	Clinical Study Site	West Palm Beach33401	NCT06767514	Map
FL	Florida Cancer Specialists & Research Institute (FCS)-South	West Palm Beach33401	NCT05899608	Map
GA	Clinical Study Site	Atlanta30318	NCT06767514	Map
GA	Winship Cancer Institute of Emory University	Atlanta30322	NCT01042379	Map
GA	Central Georgia Cancer Care	Macon31210	NCT05899608	Map
GA	Clinical Study Site	Macon30318	NCT06767514	Map
GA	Clinical Study Site	Macon31210	NCT06767514	Map
GA	Clinical Study Site	Newnan30265	NCT07228832	Map
IL	Clinical Study Site	Carterville62918	NCT06767514	Map
IL	Clinical Study Site	Chicago60611	NCT07228832	Map
IL	Northwestern Memorial Hospital	Chicago60611	NCT05899608	Map
IL	University of Chicago	Chicago60453	NCT01042379	Map
IL	Clinical Study Site	Elmhurst60540	NCT07228832	Map
IL	Loyola University	Maywood60153	NCT01042379	Map
IL	Clinical Study Site	O'Fallon62269	NCT07228832	Map
IL	Illinois Cancer Care	Peoria61615	NCT05899608	Map
IN	Clinical Study Site	Fort Wayne46804	NCT07228832	Map
IN	Clinical Study Site	Indianapolis46237	NCT06767514	Map
IN	Clinical Study Site	Indianapolis46202	NCT07228832	Map
IA	Clinical Study Site	Waukee50263	NCT06767514	Map
KS	University of Kansas Cancer Center	Westwood66205	NCT05899608	Map
KY	Clinical Study Site	Edgewood41017	NCT07228832	Map
KY	Baptist Health	Lexington40503	NCT05899608	Map
KY	Clinical Study Site	Lexington40503	NCT06767514	Map
LA	Clinical Study Site	Covington70433	NCT06767514	Map
MD	Ascension Saint Agnes Hospital	Baltimore21229	NCT05899608	Map
MD	Clinical Study Site	Baltimore21229	NCT06767514	Map
MD	Sidney Kimmel Comprehensive Cancer Center	Baltimore21187	NCT05899608	Map
MA	Brigham and Women's Hospital	Boston02115	NCT06805617	Map
MA	Clinical Study Site	Boston02215	NCT06767514	Map
MA	Dana-Farber Cancer Institute	Boston02115	NCT06805617	Map
MA	Massachusetts General Hospital	Boston02114	NCT07070466	Map
MA	Lahey Hospital	Burlington01805	NCT05899608	Map
MA	Clinical Study Site	Milton02186	NCT06767514	Map
MA	Clinical Study Site	Worcester01655	NCT06767514	Map
MI	Trinity Health	Ann Arbor48197	NCT05899608	Map
MI	University of Michigan	Ann Arbor48109	NCT05899608	Map
MI	University of Michigan Comprehensive Cancer Center	Ann Arbor48109	NCT07094685	Map
MI	Clinical Study Site	Detroit48202	NCT06767514	Map
MI	Clinical Study Sites	Detroit48202	NCT06767514	Map
MI	Henry Ford Hospital	Detroit48202	NCT05899608	Map
MI	Karmanos Cancer Insitute	Detroit48201	NCT05899608	Map
MI	Clinical Study Site	Lansing48910	NCT06767514	Map
MI	Herbert-Herman Cancer Center, Sparrow Hospital	Lansing48912	NCT01042379	Map
MN	Clinical Study Site	Minneapolis55455	NCT06767514	Map
MN	University of Minnesota	Minneapolis55455	NCT01042379	Map
MN	Mayo Clinic	Rochester55905	NCT01042379	Map
MN	Mayo Clinic	Rochester55905	NCT05899608	Map
MN	Clinical Study Site	Saint Louis Park55426	NCT06767514	Map
MN	Clinical Study Site	Saint Louis Park55426	NCT07228832	Map
MN	Metro Minnesota Community Oncology Research Consortium, Hennepin County Medical Center	Saint Louis Park55416	NCT01042379	Map
MN	Clinical Study Site	Saint Paul55101	NCT06767514	Map
MN	Park Nicollet Institute	Saint Paul55101	NCT05899608	Map
MS	Clinical Study Site	Hattiesburg39401	NCT06767514	Map
MO	American Oncology Partners, PA	Kansas City64132	NCT05899608	Map
MO	Clinical Study Site	Kansas City64132	NCT06767514	Map
MO	Clinical Study Site	St Louis63128	NCT06767514	Map
MO	Washington University St.Louis	St Louis63110	NCT05899608	Map
MT	Clinical Study Site	Billings59102	NCT07228832	Map
MT	St. Vincent Cancer Center	Billings59102	NCT05899608	Map
NE	Clinical Study Site	Lincoln68506	NCT07228832	Map
NE	University of Nebraska Medical Center (UNMC)	Omaha68105	NCT05899608	Map
NH	Clinical Study Site	Lebanon03756	NCT06767514	Map
NH	Dartmouth-Hitchcock Medical Center	Lebanon03756	NCT05899608	Map
NJ	Clinical Study Site	Basking Ridge07920	NCT06767514	Map
NJ	Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)	Basking Ridge07920	NCT07516925	Map
NJ	Memorial Sloan Kettering Basking Ridge (All Protocol Activities)	Basking Ridge07920	NCT06925724	Map
NJ	Memorial Sloan Kettering Basking Ridge (All Protocol Activities)	Basking Ridge07920	NCT07535437	Map
NJ	Memorial Sloan Kettering Basking Ridge (All Protocol Activities)	Basking Ridge07920	NCT07535463	Map
NJ	Clinical Study Site	Middletown07748	NCT06767514	Map
NJ	Memorial Sloan Kettering Monmouth (All Protocol Activities)	Middletown07748	NCT06925724	Map
NJ	Memorial Sloan Kettering Monmouth (All Protocol Activities)	Middletown07748	NCT07535437	Map
NJ	Memorial Sloan Kettering Monmouth (All Protocol Activities)	Middletown07748	NCT07535463	Map
NJ	Memorial Sloan Kettering Monmouth (Limited Protocol Activities)	Middletown07748	NCT07516925	Map
NJ	Clinical Study Site	Montvale07645	NCT06767514	Map
NJ	Memorial Sloan Kettering Bergen (All Protocol Activities)	Montvale07645	NCT06925724	Map
NJ	Memorial Sloan Kettering Bergen (All Protocol Activities)	Montvale07645	NCT07535437	Map
NJ	Memorial Sloan Kettering Bergen (All Protocol Activities)	Montvale07645	NCT07535463	Map
NJ	Memorial Sloan Kettering Bergen (Limited Protocol Activities)	Montvale07645	NCT07516925	Map
NJ	Clinical Study Site	Mullica Hill08062	NCT06767514	Map
NJ	Clinical Study Site	New Brunswick08901	NCT06767514	Map
NJ	Clinical Study Site	New Brunswick08901	NCT07228832	Map
NJ	Rutgers Cancer Institute	New Brunswick08901	NCT07057791	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08903	NCT01042379	Map
NY	Roswell Park Cancer Institute	Buffalo14263	NCT01042379	Map
NY	Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)	Commack11725	NCT07535437	Map
NY	Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)	Commack11725	NCT07535463	Map
NY	Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)	Commack11725	NCT07516925	Map
NY	Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities)	Commack11725	NCT06925724	Map
NY	Clinical Study Site	Glen Falls12801	NCT06767514	—
NY	Clinical Study Site	Harrison10604	NCT06767514	Map
NY	Memorial Sloan Kettering Westchester (All Protocol Activities)	Harrison10604	NCT06925724	Map
NY	Memorial Sloan Kettering Westchester (All Protocol Activities)	Harrison10604	NCT07535437	Map
NY	Memorial Sloan Kettering Westchester (All Protocol Activities)	Harrison10604	NCT07535463	Map
NY	Memorial Sloan Kettering Westchester (Limited Protocol Activities)	Harrison10604	NCT07516925	Map
NY	Clinical Study Site	Mineola11501	NCT07228832	Map
NY	Clinical Study Site	New York10065	NCT06767514	Map
NY	Clinical Study Site	New York10016	NCT07228832	Map
NY	Columbia University Medical Center	New York10032	NCT01042379	Map
NY	Laura and Isaac Perlmutter Cancer Center / NYU Langone Health	New York10016	NCT01042379	Map
NY	Memorial Sloan Kettering	New York10065	NCT05899608	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT07516925	Map
NY	Memorial Sloan Kettering Cancer Center (All Protocol Activities)	New York10065	NCT06925724	Map
NY	Memorial Sloan Kettering Cancer Center (All Protocol Activities)	New York10065	NCT07535437	Map
NY	Memorial Sloan Kettering Cancer Center (All Protocol Activities)	New York10065	NCT07535463	Map
NY	Mount Sinai	New York10029	NCT05899608	Map
NY	University of Rochester Wilmot Cancer Institute	Rochester14642	NCT01042379	Map
NY	Memorial Sloan Kettering Nassau (All Protocol Activities)	Rockville Centre11553	NCT07535463	Map
NY	Memorial Sloan Kettering Nassau (Limited Protocol Activities)	Rockville Centre11553	NCT07516925	Map
NY	Clinical Study Site	Syracuse13210	NCT06767514	Map
NY	SUNY Upstate Medical University	Syracuse13210	NCT05899608	Map
NY	Clinical Study Site	The Bronx10461	NCT07228832	Map
NY	Montefiore Medical Center	The Bronx10467	NCT01042379	Map
NY	Montefiore Medical Center- Montefiore Medical Park	The Bronx10461	NCT07057791	Map
NY	Clinical Study Site	Uniondale11553	NCT06767514	Map
NY	Memorial Sloan Kettering Nassau (All Protocol Activities)	Uniondale11553	NCT06925724	Map
NY	Memorial Sloan Kettering Nassau (All Protocol Activities)	Uniondale11553	NCT07535437	Map
NC	Clinical Study Site	Chapel Hill27592	NCT06767514	Map
NC	University of North Carolina	Chapel Hill27514	NCT05899608	Map
NC	Levine Center	Charlotte28204	NCT05899608	Map
NC	Wake Forest Baptist Comprehensive Cancer Center	Winston-Salem27157	NCT01042379	Map
OH	Clinical Study Site	Akron44032	NCT07228832	Map
OH	Clinical Study Site	Canton44703	NCT07228832	Map
OH	Clinical Study Site	Cincinnati45219	NCT07228832	Map
OH	Clinical Study Site	Cincinnati45220	NCT07228832	Map
OH	Oncology Hematology Care (OHC), Inc	Cincinnati45242	NCT05899608	Map
OH	Cleveland Clinic	Cleveland44106	NCT01042379	Map
OH	Cleveland Clinic	Cleveland44195	NCT05899608	Map
OH	Clinical Study Site	Cleveland44111	NCT07228832	Map
OH	Clinical Study Site	Cleveland44195	NCT07228832	Map
OH	University Hospitals Case Medical Center	Cleveland44106	NCT05899608	Map
OH	Clinical Study Site	Columbus43219	NCT06767514	Map
OH	The Ohio State University, Stefanie Spielman Comprehensive Breast Center	Columbus43212	NCT01042379	Map
OH	Clinical Study Sites	Lebanon45036	NCT06767514	Map
OH	Clinical Study Site	Mayfield Heights44124	NCT07228832	Map
OK	Clinical Study Site	Oklahoma City73102	NCT06767514	Map
OR	Clinical Study Site	Eugene97401	NCT06767514	Map
OR	Willamette Valley Cancer Institute and Research Center (WVCI)	Eugene97401	NCT05899608	Map
OR	Clinical Study Site	Portland97239	NCT06767514	Map
OR	Oregon Health & Science Institute (OHSU)	Portland97239	NCT01042379	Map
PA	Clinical Study Site	Philadelphia19111	NCT06767514	Map
PA	Clinical Study Site	Philadelphia19111	NCT07228832	Map
PA	Clinical Study Site	Philadelphia19140	NCT07228832	Map
PA	Fox Chase Cancer Center	Philadelphia19111	NCT07057791	Map
PA	University of Pennsylvania (U Penn)	Philadelphia19104	NCT01042379	Map
PA	Clinical Study Site	Pittsburgh15232	NCT06767514	Map
PA	Guthrie	Sayre18840	NCT07057791	Map
SC	Medical University of South Carolina (MUSC)	Charleston29425	NCT05899608	Map
SC	Prisma Health-Upstate	Greenville29605	NCT05899608	Map
SD	Sanford Clinical Research	Sioux Falls57104	NCT01042379	Map
TN	Clinical Study Site	Hermitage37129	NCT07228832	Map
TN	West Cancer Center	Memphis38138	NCT05899608	Map
TN	Clinical Study Site	Nashville37235	NCT06767514	Map
TN	SCRI-Nashville	Nashville37203	NCT05899608	Map
TN	Tennessee Oncology	Nashville37023	NCT07397338	Map
TX	Clinical Study Site	Abilene79601	NCT06767514	Map
TX	Clinical Study Site	Austin78745	NCT06767514	Map
TX	Texas Oncology- Austin	Austin78745	NCT05899608	Map
TX	Clinical Study Site	Dallas75246	NCT06767514	Map
TX	Texas Oncology-Dallas	Dallas75246	NCT05899608	Map
TX	UT Southwestern Medical Center	Dallas75390	NCT05899608	Map
TX	Clinical Study Site	Fort Worth76104	NCT07228832	Map
TX	Clinical Study Site	Forth Worth76104	NCT06767514	—
TX	Clinical Study Site	Houston77030	NCT06767514	Map
TX	Houston Methodist Hospital	Houston77030	NCT05899608	Map
TX	MD Anderson Cancer Center	Houston77030	NCT06567314	Map
TX	MD Anderson Cancer Center	Houston77030	NCT05899608	Map
TX	MD Anderson Cancer Center	Houston77030	NCT06940518	Map
TX	MD Anderson Cancer Center	Houston77030	NCT07229417	Map
TX	The University of Texas M. D. Anderson Cancer Center	Houston77030	NCT06672575	Map
TX	The University of Texas M. D. Anderson Cancer Center	Houston77030	NCT06959550	Map
TX	The University of Texas MD Anderson Cancer Center	Houston77030	NCT06672575	Map
TX	NEXT Dallas	Irving75039	NCT07397338	Map
TX	NEXT Oncology	San Antonio78229	NCT07397338	Map
TX	Texas Oncology-San Antonio	San Antonio78216	NCT05899608	Map
TX	Clinical Study Site	Tyler75708	NCT06767514	Map
TX	Texas Oncology-Tyler	Tyler75702	NCT05899608	Map
TX	University of Texas at Tyler	Tyler75708	NCT05899608	Map
TX	Clinical Study Site	Webster77598	NCT06767514	Map
UT	Clinical Study Site	Salt Lake City84106	NCT06767514	Map
UT	Clinical Study Site	Salt Lake City84106	NCT07228832	Map
UT	Huntsman Cancer Institute, University of Utah	Salt Lake City84112	NCT01042379	Map
VA	Clinical Study Site	Blacksburg24060	NCT06767514	Map
VA	Clinical Study Site	Charlottesville22908	NCT06767514	Map
VA	Clinical Study Site	Charlottesville22908	NCT07228832	Map
VA	Universtiy of Virginia	Charlottesville22908	NCT07057791	Map
VA	Clinical Study Site	Fairfax22031	NCT06767514	Map
VA	NEXT Virginia	Fairfax22031	NCT07397338	Map
VA	Virginia Oncology Associates	Norfolk23502	NCT05899608	Map
VA	Virginia Cancer	Reston20190	NCT05899608	Map
VA	Clinical Study Site	Richmond23229	NCT06767514	Map
VA	Clinical Study Site	Richmond23298	NCT06767514	Map
WA	Clinical Study Site	Seattle98109	NCT06767514	Map
WA	Swedish Cancer Institute	Seattle98103	NCT05899608	Map
WA	Cancer Care NW Centers	Spokane99202	NCT05899608	Map
WA	Clinical Study Site	Spokane99208	NCT07228832	Map
WA	Clinical Study Site	Tacoma98405	NCT07228832	Map
WA	Clinical Study Site	Vancouver98684	NCT06767514	Map
WV	Clinical Study Site	Charleston25304	NCT07228832	Map
WI	Carbone Cancer Center	Madison53792	NCT05899608	Map
WI	Aspirus Cancer Center Wausau	Wausau54401	NCT07057791	Map

Ivonescimab clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	enrolling by invitation	withdrawn	not yet recruiting	Total
P1	1				2	3
P1/P2	7				3	10
P2	34			1	29	64
P3	6	1				7
N/A	1		1		1	3

Recruiting Ivonescimab clinical trials (85)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT07359456	COLIBRI-GITesting Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases	P2	Metastatic Colorectal Cancer	130	Aug 2026
NCT07244978	Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma	P2	Esophageal Squamous Cell Carcinoma	49	Jun 2026
NCT07017673	Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer	P2	TNBC	34	Jul 2025
NCT07234877	Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets	P2	Non Small Cell Lung Cancer	158	Nov 2026
NCT06977542	Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer	P2	TNBC, Triple Negative Breast Cancer	53	Jun 2025
NCT01042379	I-SPYI-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	P2	Breast Neoplasms	5,000	Mar 2010
NCT06760520	Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer	P2	Locally Advanced Rectal Cancer	40	Jan 2025
NCT07565389	AK112Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma	P2	Nasopharyngeal Carcinoma (NPC)	42	May 2026
NCT07094685	SENIOR-HNIvonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer	P2	Advanced Head and Neck Squamous Cell Carcinoma	28	Nov 2025
NCT07560124	A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer	P1/P2	Breast Cancer	286	Jun 2026
NCT06567314	Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma	P2	Cutaneous Squamous Cell Carcinoma	24	Dec 2024
NCT06959550	Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer	P2	Metastatic Colorectal Cancer	90	Jul 2025
NCT06928389	NSCLCIvonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer	P3	Non-Small Cell Lung Cancer	536	Jul 2025
NCT06951646	ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)	P2	Non Small Cell Lung Cancer	70	Mar 2026
NCT07264075	ILLUMINEStudy Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN	P3	Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)	780	May 2026
NCT06814067	SOCPhase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma	P2	Head and Neck Squamous Cell Carcinoma	80	Feb 2025
NCT07057791	PrE0510Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer	P2	Extensive Stage Lung Small Cell Cancer	60	Mar 2026
NCT06672575	A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma	P1/P2	Glioblastoma	45	Jan 2025
NCT06940518	Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma	P2	Ivonescimab	40	Jul 2025
NCT06875076	AK112Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesothelioma	P2	Pretreated Pleural Mesothelioma	25	Mar 2025
NCT05899608	Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients	P3	Non-Small Cell Lung Cancer	1,600	Oct 2023
NCT07393555	Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)	P2	Recurrent Lung Non-Small Cell Carcinoma	117	Aug 2026
NCT07228832	HARMONi-GI3Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer	P3	Metastatic Colorectal Cancer (CRC)	600	Nov 2025
NCT07204548	IVO LungThe IVO-LUNG Study	P2	Non Small Cell Lung Cancer (Stage III)	63	Oct 2025
NCT07339839	Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC	P1/P2	NSCLC Stage IV	42	Mar 2026
NCT07229417	IvoLoC Trial: A Phase II Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma	P2	Metastatic Endocrine Refractory	29	Oct 2025
NCT05582499	FASCINATE-NFudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy	P2	Breast Neoplasm	716	Nov 2022
NCT07158489	ORIGIN2Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC	P2	NSCLC	47	Jul 2026
NCT07244965	Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer	P2	LOCALLY ADVANCED CERVICAL CANCERS	42	Dec 2025
NCT06767514	HARMONi-7Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1	P3	Non-Small Cell Lung Cancer	780	Feb 2025
NCT07381075	ADCA Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma	P2	Head and Neck Squamous Cell Carcinoma	120	Feb 2026
NCT07397338	ONStudy of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors	P1/P2	Advanced Solid Tumors	370	Jan 2026
NCT06957561	DIVONDisitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer	P1/P2	Bladder Cancer	30	Apr 2025
NCT07516925	A Study of Ivonescimab in People With Leiomyosarcoma	P2	Leiomyosarcoma	20	Apr 2026
NCT07412262	NSCLC， YAPA Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression	P2	Non-Small Cell Lung Cancer	32	May 2026
NCT06877650	First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors	P1/P2	Advanced Malignant Tumors	436	Apr 2025
NCT07405190	Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC	P2	Lung Cancer (NSCLC)	46	Aug 2026
NCT06529718	SEVILLATesting Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients	P2	Biliary Tract Cancer	72	Oct 2025
NCT07394218	ctDNA-guided Treatment Decision-making	P2	Metastatic Breast Cancer ( HER2 Negative)	122	Dec 2025
NCT07162714	STARSCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer	P2	Rectal Cancer	30	Sep 2025
NCT06868732	Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC	P1	Advanced Non-small Cell Lung Cancer	288	Apr 2025
NCT06750952	iTHYMIvonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial	P2	Relapsed or Metastatic Thymic Cancer	24	Dec 2024
NCT07241819	Ivonescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant/Adjuvant Therapy for Resectable Non-small Cell Lung Cancer	P2	II-IIIB (T3N2) Resectable Non-small Cell Lung Cancer	66	Nov 2025
NCT06913218	A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC	P1	Pancreas Cancer	60	Jul 2025
NCT06846346	GRACIETesting Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma	P2	Metastatic Esophageal Adenocarcinoma	88	Nov 2025
NCT07070466	Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA	P2	Stomach Cancer Stage IV	40	Oct 2025
NCT06145308	Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing	P2	Salivary Gland Carcinoma	39	Aug 2023
NCT07245446	A Study of Ivonescimab in First-Line ES-SCLC	P2	Extensive-stage Small Cell Lung Cancer (ES-SCLC)	180	Oct 2025
NCT07064902	Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma	P2	Nasopharyngeal Carcinoma (NPC)	48	Aug 2025
NCT06790212	Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer	P2	Colon Cancer	168	Apr 2025
NCT06980077	Ivonescimab for the Treatment of Thymic Cancer	P2	Thymus Carcinoma	25	Jul 2025
NCT07009925	Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC.	P2	Squamous Cell Lung Cancer	38	Jun 2025
NCT06953999	A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer	P3	Pancreatic Cancer	999	Jun 2025
NCT07535463	A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer	P1/P2	Non-Small Cell Lung Cancer	53	Apr 2026
NCT07535437	A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer	P1/P2	Non-Small Cell Lung Cancer	66	Apr 2026
NCT07472478	GIVENPhase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)	P2	Lung Cancer (NSCLC)	32	Mar 2026
NCT06840834	Bi-MAPSEvaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy	P2	Pleural Mesotheliomas	38	Jun 2025
NCT06844422	ASCENDAdapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)	P1/P2	Pancreatic Cancer	37	Feb 2025
NCT07070479	Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial	P2	Recurrent or Metastatic Nasopharyngeal Carcinoma	208	Jun 2025
NCT07374250	HuaxiPerioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma	P2	Gastric Cancer	154	Feb 2026
NCT07208773	AK112A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors	P1/P2	Advanced Solid Tumors	260	Oct 2025
NCT06820762	IIIrinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study	P2	SCLC	40	Feb 2025
NCT06769971	Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC	P2	Small Cell Lung Cancer	80	Feb 2025
NCT07086326	NEOINSPIREA Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC	P2	NSCLC	164	Jul 2025
NCT06802666	Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer	P2	Locally Advanced Rectal Cancer	45	Oct 2024
NCT06444009	A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma	P2	Head and Neck Squamous Cell Carcinoma	90	Jul 2024
NCT07359040	Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer	—	Non-Small Cell Lung Cancer	80	Jul 2025
NCT07226544	Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer	P2	Localized Clear Cell Renal Cell Carcinoma	31	Jun 2026
NCT06478043	A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for ES-SCLC	P2	Extensive-stage Small-cell Lung Cancer	54	Sep 2024
NCT06489197	AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients	P2	ESCC	30	Nov 2024
NCT07363408	Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer	P1	Advanced Microsatellite Stable Colorectal Carcinoma	30	Jul 2026
NCT06491472	Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer	P2	Pancreatic Cancer	36	Jul 2024
NCT06805617	I-MACA Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers	P2	Salivary Gland Cancer	35	Feb 2025
NCT06848842	Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases	P2	Colorectal Liver Metastases	40	Sep 2025
NCT07188103	Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma	P2	Esophageal Squamous Cell Carcinoma	37	Jul 2025
NCT06993025	Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies	P2	Biliary Tract Cancer	30	May 2025
NCT06925724	A Study of Ivonescimab in People With Endometrial and Cervical Cancers	P2	Endometrial Cancer	50	Apr 2025
NCT06196697	AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer	P2	Gastric Adenocarcinoma	50	Apr 2024
NCT07095803	Ivonescimab (PD-1/VEGF Bispecific Antibody) Plus Radiofrequency Ablation for Multiple Advanced Tumors After PD-1 Therapy Failure	P2	Multiple Advanced Tumors After PD-1 Therapy Failure	60	Aug 2025
NCT06793332	BALISTABrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC	P2	Triple-Negative Breast Cancer (TNBC)	39	Dec 2024
NCT06814158	Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer	P2	Esophageal Squamour Cell Cancer	57	Mar 2025
NCT06936488	AK112A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combined With TAS-102 in the Treatment of Refractory MSS/pMMR Advanced Colorectal Cancer	N/A	MSS/pMMR Type Metastatic Colorectal Adenocarcinoma Patients	35	Mar 2025
NCT06991491	WGOG-PAN 004Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004)	P2	Pancreatic Cancer	29	Jun 2025
NCT06375486	Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.	P2	Hepatocellular Carcinoma Non-resectable	30	Mar 2024
NCT06766591	Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs	N/A	NSCLC	36	Jan 2025

Ivonescimab clinical trials by indication

Non-Small Cell Lung Cancer (7)

NCT	Acronym	Phase	Status	Title
NCT06928389	NSCLC	P3	recruiting	Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
NCT05899608	—	P3	recruiting	Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT06767514	HARMONi-7	P3	recruiting	Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT07412262	NSCLC， YAP	P2	not yet recruiting	A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression
NCT07535463	—	P1/P2	recruiting	A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer
NCT07535437	—	P1/P2	recruiting	A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer
NCT07359040	—	N/A	recruiting	Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer

Pancreatic Cancer (4)

NCT	Acronym	Phase	Status	Title
NCT06953999	—	P3	recruiting	A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
NCT06844422	ASCEND	P1/P2	recruiting	Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)
NCT06491472	—	P2	recruiting	Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer
NCT06991491	WGOG-PAN 004	P2	not yet recruiting	Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004)

NSCLC (3)

NCT	Acronym	Phase	Status	Title
NCT07158489	ORIGIN2	P2	not yet recruiting	Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC
NCT07086326	NEOINSPIRE	P2	not yet recruiting	A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
NCT06766591	—	N/A	not yet recruiting	Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs

Head and Neck Squamous Cell Carcinoma (3)

NCT	Acronym	Phase	Status	Title
NCT06814067	SOC	P2	not yet recruiting	Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07381075	ADC	P2	not yet recruiting	A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT06444009	—	P2	recruiting	A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

Lung Cancer (NSCLC) (2)

NCT	Acronym	Phase	Status	Title
NCT07405190	—	P2	not yet recruiting	Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
NCT07472478	GIVEN	P2	not yet recruiting	Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)

Esophageal Squamous Cell Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT07244978	—	P2	not yet recruiting	Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
NCT07188103	—	P2	recruiting	Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma

Nasopharyngeal Carcinoma (NPC) (2)

NCT	Acronym	Phase	Status	Title
NCT07565389	AK112	P2	not yet recruiting	Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT07064902	—	P2	not yet recruiting	Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma

Non Small Cell Lung Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT07234877	—	P2	not yet recruiting	Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets
NCT06951646	—	P2	recruiting	ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

Metastatic Colorectal Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT07359456	COLIBRI-GI	P2	not yet recruiting	Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases
NCT06959550	—	P2	recruiting	Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer

Advanced Solid Tumors (2)

NCT	Acronym	Phase	Status	Title
NCT07397338	ON	P1/P2	recruiting	Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
NCT07208773	AK112	P1/P2	recruiting	A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors

Biliary Tract Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT06529718	SEVILLA	P2	recruiting	Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
NCT06993025	—	P2	not yet recruiting	Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies

Locally Advanced Rectal Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT06760520	—	P2	not yet recruiting	Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer
NCT06802666	—	P2	recruiting	Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Recurrent Lung Non-Small Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07393555	—	P2	not yet recruiting	Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)

Advanced Microsatellite Stable Colorectal Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07363408	—	P1	not yet recruiting	Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer

Localized Clear Cell Renal Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07226544	—	P2	recruiting	Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer

Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07560124	—	P1/P2	not yet recruiting	A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer

Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) (1)

NCT	Acronym	Phase	Status	Title
NCT07264075	ILLUMINE	P3	recruiting	Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN

Leiomyosarcoma (1)

NCT	Acronym	Phase	Status	Title
NCT07516925	—	P2	recruiting	A Study of Ivonescimab in People With Leiomyosarcoma

Extensive Stage Lung Small Cell Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07057791	PrE0510	P2	recruiting	Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer

NSCLC Stage IV (1)

NCT	Acronym	Phase	Status	Title
NCT07339839	—	P1/P2	not yet recruiting	Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC

Gastric Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07374250	Huaxi	P2	not yet recruiting	Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma

Metastatic Breast Cancer ( HER2 Negative) (1)

NCT	Acronym	Phase	Status	Title
NCT07394218	—	P2	recruiting	ctDNA-guided Treatment Decision-making

LOCALLY ADVANCED CERVICAL CANCERS (1)

NCT	Acronym	Phase	Status	Title
NCT07244965	—	P2	not yet recruiting	Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer

II-IIIB (T3N2) Resectable Non-small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07241819	—	P2	not yet recruiting	Ivonescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant/Adjuvant Therapy for Resectable Non-small Cell Lung Cancer

Metastatic Esophageal Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06846346	GRACIE	P2	recruiting	Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma

Metastatic Colorectal Cancer (CRC) (1)

NCT	Acronym	Phase	Status	Title
NCT07228832	HARMONi-GI3	P3	recruiting	Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

Advanced Head and Neck Squamous Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07094685	SENIOR-HN	P2	recruiting	Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer

Non Small Cell Lung Cancer (Stage III) (1)

NCT	Acronym	Phase	Status	Title
NCT07204548	IVO Lung	P2	not yet recruiting	The IVO-LUNG Study

Extensive-stage Small Cell Lung Cancer (ES-SCLC) (1)

NCT	Acronym	Phase	Status	Title
NCT07245446	—	P2	recruiting	A Study of Ivonescimab in First-Line ES-SCLC

Metastatic Endocrine Refractory (1)

NCT	Acronym	Phase	Status	Title
NCT07229417	—	P2	recruiting	IvoLoC Trial: A Phase II Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma

Stomach Cancer Stage IV (1)

NCT	Acronym	Phase	Status	Title
NCT07070466	—	P2	recruiting	Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

Colorectal Liver Metastases (1)

NCT	Acronym	Phase	Status	Title
NCT06848842	—	P2	recruiting	Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases

Rectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07162714	STAR	P2	not yet recruiting	SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer

Multiple Advanced Tumors After PD-1 Therapy Failure (1)

NCT	Acronym	Phase	Status	Title
NCT07095803	—	P2	not yet recruiting	Ivonescimab (PD-1/VEGF Bispecific Antibody) Plus Radiofrequency Ablation for Multiple Advanced Tumors After PD-1 Therapy Failure

Lung Squamous Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07038915	STRIVE	P2	withdrawn	STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1

TNBC (1)

NCT	Acronym	Phase	Status	Title
NCT07017673	—	P2	recruiting	Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

Pancreas Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06913218	—	P1	not yet recruiting	A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC

Thymus Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06980077	—	P2	recruiting	Ivonescimab for the Treatment of Thymic Cancer

Ivonescimab (1)

NCT	Acronym	Phase	Status	Title
NCT06940518	—	P2	recruiting	Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma

Pleural Mesotheliomas (1)

NCT	Acronym	Phase	Status	Title
NCT06840834	Bi-MAPS	P2	recruiting	Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy

TNBC, Triple Negative Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06977542	—	P2	not yet recruiting	Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer

Squamous Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07009925	—	P2	not yet recruiting	Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC.

Recurrent or Metastatic Nasopharyngeal Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07070479	—	P2	recruiting	Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

Bladder Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06957561	DIVON	P1/P2	not yet recruiting	Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Colon Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06790212	—	P2	not yet recruiting	Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer

Advanced Malignant Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT06877650	—	P1/P2	recruiting	First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors

Endometrial Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06925724	—	P2	recruiting	A Study of Ivonescimab in People With Endometrial and Cervical Cancers

Advanced Non-small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06868732	—	P1	recruiting	Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC

Pretreated Pleural Mesothelioma (1)

NCT	Acronym	Phase	Status	Title
NCT06875076	AK112	P2	recruiting	Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesothelioma

Esophageal Squamour Cell Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06814158	—	P2	not yet recruiting	Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer

MSS/pMMR Type Metastatic Colorectal Adenocarcinoma Patients (1)

NCT	Acronym	Phase	Status	Title
NCT06936488	AK112	N/A	enrolling by invitation	A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combined With TAS-102 in the Treatment of Refractory MSS/pMMR Advanced Colorectal Cancer

SCLC (1)

NCT	Acronym	Phase	Status	Title
NCT06820762	II	P2	not yet recruiting	Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study

Salivary Gland Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06805617	I-MAC	P2	recruiting	A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers

Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06769971	—	P2	recruiting	Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC

Glioblastoma (1)

NCT	Acronym	Phase	Status	Title
NCT06672575	—	P1/P2	recruiting	A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma

Relapsed or Metastatic Thymic Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06750952	iTHYM	P2	not yet recruiting	Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial

Triple-Negative Breast Cancer (TNBC) (1)

NCT	Acronym	Phase	Status	Title
NCT06793332	BALISTA	P2	recruiting	BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC

Cutaneous Squamous Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06567314	—	P2	recruiting	Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma

ESCC (1)

NCT	Acronym	Phase	Status	Title
NCT06489197	—	P2	recruiting	AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients

Extensive-stage Small-cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06478043	—	P2	not yet recruiting	A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for ES-SCLC

Gastric Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06196697	—	P2	recruiting	AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

Hepatocellular Carcinoma Non-resectable (1)

NCT	Acronym	Phase	Status	Title
NCT06375486	—	P2	recruiting	Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.

Salivary Gland Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06145308	—	P2	recruiting	Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Breast Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT05582499	FASCINATE-N	P2	recruiting	Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Non-Squamous Non-small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05184712	—	P3	active not recruiting	Phase 3 Clinical Study of AK112 for NSCLC Patients

Breast Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT01042379	I-SPY	P2	recruiting	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Ivonescimab pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
NSCLC	NCT06928389	P3	recruiting	Non-Small Cell Lung Cancer	536	—
ILLUMINE	NCT07264075	P3	recruiting	Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)	780	—
HARMONi-GI3	NCT07228832	P3	recruiting	Metastatic Colorectal Cancer (CRC)	600	—
HARMONi-7	NCT06767514	P3	recruiting	Non-Small Cell Lung Cancer	780	—
COLIBRI-GI	NCT07359456	P2	not yet recruiting	Metastatic Colorectal Cancer	130	—
I-SPY	NCT01042379	P2	recruiting	Breast Neoplasms	5,000	PMID 21796368
AK112	NCT07565389	P2	not yet recruiting	Nasopharyngeal Carcinoma (NPC)	42	PMID 15950718
SENIOR-HN	NCT07094685	P2	recruiting	Advanced Head and Neck Squamous Cell Carcinoma	28	—
SOC	NCT06814067	P2	not yet recruiting	Head and Neck Squamous Cell Carcinoma	80	PMID 35338369
PrE0510	NCT07057791	P2	recruiting	Extensive Stage Lung Small Cell Cancer	60	—
AK112	NCT06875076	P2	recruiting	Pretreated Pleural Mesothelioma	25	—
IVO Lung	NCT07204548	P2	not yet recruiting	Non Small Cell Lung Cancer (Stage III)	63	PMID 28885881
FASCINATE-N	NCT05582499	P2	recruiting	Breast Neoplasm	716	PMID 38362377
ORIGIN2	NCT07158489	P2	not yet recruiting	NSCLC	47	—
ADC	NCT07381075	P2	not yet recruiting	Head and Neck Squamous Cell Carcinoma	120	—
NSCLC， YAP	NCT07412262	P2	not yet recruiting	Non-Small Cell Lung Cancer	32	—
SEVILLA	NCT06529718	P2	recruiting	Biliary Tract Cancer	72	—
STAR	NCT07162714	P2	not yet recruiting	Rectal Cancer	30	—
iTHYM	NCT06750952	P2	not yet recruiting	Relapsed or Metastatic Thymic Cancer	24	—
GRACIE	NCT06846346	P2	recruiting	Metastatic Esophageal Adenocarcinoma	88	—
GIVEN	NCT07472478	P2	not yet recruiting	Lung Cancer (NSCLC)	32	—
Bi-MAPS	NCT06840834	P2	recruiting	Pleural Mesotheliomas	38	—
Huaxi	NCT07374250	P2	not yet recruiting	Gastric Cancer	154	PMID 33852952
II	NCT06820762	P2	not yet recruiting	SCLC	40	PMID 38648575
NEOINSPIRE	NCT07086326	P2	not yet recruiting	NSCLC	164	—
I-MAC	NCT06805617	P2	recruiting	Salivary Gland Cancer	35	—
BALISTA	NCT06793332	P2	recruiting	Triple-Negative Breast Cancer (TNBC)	39	PMID 37593227
WGOG-PAN 004	NCT06991491	P2	not yet recruiting	Pancreatic Cancer	29	—
STRIVE	NCT07038915	P2	withdrawn	Lung Squamous Cell Carcinoma	0	—

Terminated and withdrawn Ivonescimab trials (1)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT07038915withdrawnSTRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1

All Ivonescimab trials (87)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT07359456	COLIBRI-GI	Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases	P2	not yet recruiting	130	UNICANCER	Aug 2026
NCT07244978		Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma	P2	not yet recruiting	49	Second Affiliated Hospital, School of Medicine, Zhejiang University	Jun 2026
NCT07017673		Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer	P2	recruiting	34	Cedars-Sinai Medical Center	Jul 2025
NCT07234877		Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets	P2	not yet recruiting	158	European Organisation for Research and Treatment of Cancer - EORTC	Nov 2026
NCT06977542		Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer	P2	not yet recruiting	53	Fudan University	Jun 2025
NCT01042379	I-SPY	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	P2	recruiting	5,000	QuantumLeap Healthcare Collaborative	Mar 2010
NCT06760520		Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer	P2	not yet recruiting	40	The First Affiliated Hospital of Zhengzhou University	Jan 2025
NCT07565389	AK112	Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma	P2	not yet recruiting	42	National University Hospital, Singapore	May 2026
NCT07094685	SENIOR-HN	Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer	P2	recruiting	28	University of Michigan Rogel Cancer Center	Nov 2025
NCT07560124		A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer	P1/P2	not yet recruiting	286	Akeso	Jun 2026
NCT06567314		Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma	P2	recruiting	24	M.D. Anderson Cancer Center	Dec 2024
NCT06959550		Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer	P2	recruiting	90	M.D. Anderson Cancer Center	Jul 2025
NCT06928389	NSCLC	Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer	P3	recruiting	536	Akeso	Jul 2025
NCT06951646		ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)	P2	recruiting	70	Second Xiangya Hospital of Central South University	Mar 2026
NCT07264075	ILLUMINE	Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN	P3	recruiting	780	Groupe Oncologie Radiotherapie Tete et Cou	May 2026
NCT06814067	SOC	Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma	P2	not yet recruiting	80	Fudan University	Feb 2025
NCT07057791	PrE0510	Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer	P2	recruiting	60	PrECOG, LLC.	Mar 2026
NCT06672575		A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma	P1/P2	recruiting	45	M.D. Anderson Cancer Center	Jan 2025
NCT06940518		Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma	P2	recruiting	40	M.D. Anderson Cancer Center	Jul 2025
NCT06875076	AK112	Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesothelioma	P2	recruiting	25	The First Hospital of Jilin University	Mar 2025
NCT05899608		Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients	P3	recruiting	1,600	Summit Therapeutics	Oct 2023
NCT07393555		Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)	P2	not yet recruiting	117	SWOG Cancer Research Network	Aug 2026
NCT07228832	HARMONi-GI3	Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer	P3	recruiting	600	Summit Therapeutics	Nov 2025
NCT07204548	IVO Lung	The IVO-LUNG Study	P2	not yet recruiting	63	Sun Yat-sen University	Oct 2025
NCT07339839		Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC	P1/P2	not yet recruiting	42	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Mar 2026
NCT07229417		IvoLoC Trial: A Phase II Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma	P2	recruiting	29	M.D. Anderson Cancer Center	Oct 2025
NCT05582499	FASCINATE-N	Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy	P2	recruiting	716	Fudan University	Nov 2022
NCT07158489	ORIGIN2	Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC	P2	not yet recruiting	47	Swiss Cancer Institute	Jul 2026
NCT07244965		Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer	P2	not yet recruiting	42	Women's Hospital School Of Medicine Zhejiang University	Dec 2025
NCT06767514	HARMONi-7	Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1	P3	recruiting	780	Summit Therapeutics	Feb 2025
NCT07381075	ADC	A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma	P2	not yet recruiting	120	West China Hospital	Feb 2026
NCT07397338	ON	Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors	P1/P2	recruiting	370	Revolution Medicines, Inc.	Jan 2026
NCT06957561	DIVON	Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer	P1/P2	not yet recruiting	30	Sun Yat-sen University	Apr 2025
NCT07516925		A Study of Ivonescimab in People With Leiomyosarcoma	P2	recruiting	20	Memorial Sloan Kettering Cancer Center	Apr 2026
NCT07412262	NSCLC， YAP	A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression	P2	not yet recruiting	32	Guangdong Association of Clinical Trials	May 2026
NCT06877650		First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors	P1/P2	recruiting	436	Shanghai JMT-Bio Inc.	Apr 2025
NCT07405190		Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC	P2	not yet recruiting	46	Massachusetts General Hospital	Aug 2026
NCT06529718	SEVILLA	Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients	P2	recruiting	72	UNICANCER	Oct 2025
NCT07394218		ctDNA-guided Treatment Decision-making	P2	recruiting	122	Fudan University	Dec 2025
NCT07162714	STAR	SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer	P2	not yet recruiting	30	Zhejiang Cancer Hospital	Sep 2025
NCT06868732		Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC	P1	recruiting	288	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	Apr 2025
NCT06750952	iTHYM	Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial	P2	not yet recruiting	24	Sun Yat-sen University	Dec 2024
NCT07241819		Ivonescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant/Adjuvant Therapy for Resectable Non-small Cell Lung Cancer	P2	not yet recruiting	66	Peking University Cancer Hospital & Institute	Nov 2025
NCT06913218		A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC	P1	not yet recruiting	60	Akeso	Jul 2025
NCT06846346	GRACIE	Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma	P2	recruiting	88	UNICANCER	Nov 2025
NCT07070466		Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA	P2	recruiting	40	Massachusetts General Hospital	Oct 2025
NCT06145308		Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing	P2	recruiting	39	Peking Union Medical College	Aug 2023
NCT07245446		A Study of Ivonescimab in First-Line ES-SCLC	P2	recruiting	180	Akeso	Oct 2025
NCT07064902		Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma	P2	not yet recruiting	48	Sun Yat-sen University	Aug 2025
NCT06790212		Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer	P2	not yet recruiting	168	Sun Yat-sen University	Apr 2025
NCT06980077		Ivonescimab for the Treatment of Thymic Cancer	P2	recruiting	25	Jonsson Comprehensive Cancer Center	Jul 2025
NCT07009925		Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC.	P2	not yet recruiting	38	Jiangsu Cancer Institute & Hospital	Jun 2025
NCT06953999		A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer	P3	recruiting	999	Akeso	Jun 2025
NCT07535463		A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer	P1/P2	recruiting	53	Memorial Sloan Kettering Cancer Center	Apr 2026
NCT07535437		A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer	P1/P2	recruiting	66	Memorial Sloan Kettering Cancer Center	Apr 2026
NCT07472478	GIVEN	Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)	P2	not yet recruiting	32	Guangdong Provincial People's Hospital	Mar 2026
NCT06840834	Bi-MAPS	Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy	P2	recruiting	38	Intergroupe Francophone de Cancerologie Thoracique	Jun 2025
NCT06844422	ASCEND	Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)	P1/P2	recruiting	37	Shandong Cancer Hospital and Institute	Feb 2025
NCT07070479		Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial	P2	recruiting	208	Ming-Yuan Chen	Jun 2025
NCT07374250	Huaxi	Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma	P2	not yet recruiting	154	Sichuan University	Feb 2026
NCT07208773	AK112	A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors	P1/P2	recruiting	260	MediLink Therapeutics (Suzhou) Co., Ltd.	Oct 2025
NCT06820762	II	Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study	P2	not yet recruiting	40	The Second Affiliated Hospital of Dalian Medical University	Feb 2025
NCT06769971		Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC	P2	recruiting	80	Sichuan University	Feb 2025
NCT07086326	NEOINSPIRE	A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC	P2	not yet recruiting	164	Yang Fan, MD	Jul 2025
NCT06802666		Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer	P2	recruiting	45	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Oct 2024
NCT06444009		A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma	P2	recruiting	90	Lei Liu	Jul 2024
NCT07359040		Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer	—	recruiting	80	Peking University People's Hospital	Jul 2025
NCT07226544		Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer	P2	recruiting	31	City of Hope Medical Center	Jun 2026
NCT06478043		A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for ES-SCLC	P2	not yet recruiting	54	Zhejiang Cancer Hospital	Sep 2024
NCT06489197		AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients	P2	recruiting	30	Tianjin Medical University Cancer Institute and Hospital	Nov 2024
NCT07363408		Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer	P1	not yet recruiting	30	City of Hope Medical Center	Jul 2026
NCT06491472		Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer	P2	recruiting	36	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Jul 2024
NCT06805617	I-MAC	A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers	P2	recruiting	35	Glenn J. Hanna	Feb 2025
NCT06848842		Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases	P2	recruiting	40	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Sep 2025
NCT07188103		Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma	P2	recruiting	37	Anhui Provincial Hospital	Jul 2025
NCT06993025		Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies	P2	not yet recruiting	30	Tianjin Medical University Cancer Institute and Hospital	May 2025
NCT06925724		A Study of Ivonescimab in People With Endometrial and Cervical Cancers	P2	recruiting	50	Memorial Sloan Kettering Cancer Center	Apr 2025
NCT06196697		AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer	P2	recruiting	50	Harbin Medical University	Apr 2024
NCT07095803		Ivonescimab (PD-1/VEGF Bispecific Antibody) Plus Radiofrequency Ablation for Multiple Advanced Tumors After PD-1 Therapy Failure	P2	not yet recruiting	60	Sheng Zhang	Aug 2025
NCT06793332	BALISTA	BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC	P2	recruiting	39	Fudan University	Dec 2024
NCT06814158		Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer	P2	not yet recruiting	57	Tianjin Medical University Cancer Institute and Hospital	Mar 2025
NCT06936488	AK112	A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combined With TAS-102 in the Treatment of Refractory MSS/pMMR Advanced Colorectal Cancer	N/A	enrolling by invitation	35	Huai'an First People's Hospital	Mar 2025
NCT06991491	WGOG-PAN 004	Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004)	P2	not yet recruiting	29	West China Hospital	Jun 2025
NCT05184712		Phase 3 Clinical Study of AK112 for NSCLC Patients	P3	active not recruiting	322	Akeso	Jan 2022
NCT06375486		Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.	P2	recruiting	30	Tianjin Medical University Cancer Institute and Hospital	Mar 2024
NCT06766591		Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs	N/A	not yet recruiting	36	Jiangsu Province Nanjing Brain Hospital	Jan 2025
NCT07038915	STRIVE	STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1	P2	withdrawn	0	M.D. Anderson Cancer Center	Jul 2025

Ivonescimab clinical trials: frequently asked questions

How many Ivonescimab clinical trials are there?: 87 Ivonescimab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 50 are actively recruiting participants.
Are Ivonescimab clinical trials recruiting in 2026?: Yes — 50 Ivonescimab trials are actively recruiting in 2026, with 312 U.S. sites across 40 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Ivonescimab being studied for?: Ivonescimab is being studied for Non-Small Cell Lung Cancer, NSCLC, Neoadjuvant Therapy, Pancreatic Cancer, Breast Cancer and 129 more. The trials are grouped by indication on this page.
What phase is Ivonescimab in?: Ivonescimab clinical trials span 7 Phase 3, 64 Phase 2, 3 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Ivonescimab clinical trials?: The lead sponsor across the most Ivonescimab trials is M.D. Anderson Cancer Center, with 51 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Ivonescimabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 18, 2026.

Related pages on Hipa.ai:

Ivonescimab overview Ivonescimab evidence & publications